Key result
aPTT monitoring demonstrates significant clinical limitations during argatroban therapy.
Answers are grounded in this paper and cite their sources.
Highlights limitations of activated partial thromboplastin time for argatroban monitoring, suggesting the need for alternative coagulation assays.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Guy et al. (2016) studied this question. Activated partial thromboplastin time (aPTT) demonstrates significant limitations when used as a monitoring strategy for argatroban therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: